Titlebook: New Anticancer Drugs; Fourth Annual Progra Stephen K. Carter,Yoshia Sakurai Book 1980 Springer-Verlag Berlin Heidelberg 1980 Drugs.Zytostat

Liability

Phase II Study of Antineoplastic Agents in Japan,dence of a minimal degree of antitumor activity. Phase III is a trial to determine the degree of antitumor activity in one (or more) specific tumor type; it is usually comparative in that a control group is included.

AVANT

Introduction of U.S.-Japan Joint Meeting on Phase I and II Clinical Trials,se Society for the Promotion of Science. The USA-Japan agreement, which is now ending its fifth year, has had eleven functioning program areas. One of these program areas has been cancer treatment with emphasis on cancer chemotherapy.

GROWL

Insubordinate

CANON

Anguish

Review of Experimental Studies on Nitrosourea Derivatives in Japan,ed. These compounds are: 1-(2-chloroethyl)-3-(.-.-gluco-pyranosyl)-1-nitrosourea (GANU), 1-(2-chloroethyl)-3-(methyl-.-.-glucopyranos-6-yl)-1-nitrosourea (MCNU), .- 1-(2-chloroethyl)-3-(hexahydro-2-oxo-azepin-3-yl)-1-nitrosourea (CDL-7), and 1,1′-ethylene-bis(1-nitrosourea) (EBNU).

abject

暴露他抗議

STEER

Clinical Strategies in the Chemotherapy of Gastrointestinal Cancer,ituation. In pancreatic and colorectal cancer, combination chemotherapy regimens have been of marginal effectiveness. The major thrust of clinical investigation must be directed toward phase II evaluations of single agents in these diseases.

起草

Preclinical and Clinical Studies on Chlorozotocin, a New Nitrosourea with Decreased Bone Marrow Toxl, 16% of patients with colon cancer and 20% of patients with malignant melanoma evidenced objective regression of disease. Chlorozotocin is now undergoing phase II evaluation in combination chemotherapy trials in colon and stomach cancer.